Rexulti shortage update: What patients need to know in 2026

If you've been struggling to fill your Rexulti prescription in 2026, you're not alone. Patients across the country are reporting delays and difficulty locating their specific dose at local pharmacies. Here's a clear, up-to-date picture of what's happening with Rexulti availability in 2026.

Is there an official Rexulti shortage in 2026?

As of 2026, Rexulti (brexpiprazole) is not listed on the FDA's official drug shortage database. That means the manufacturer — Otsuka Pharmaceutical, in partnership with Lundbeck — is producing sufficient supply to meet overall national demand.

However, "no official shortage" doesn't translate to "easy to find at your pharmacy." Many patients still experience real difficulty getting Rexulti filled promptly. This is a distribution and pharmacy stocking issue, not a manufacturing crisis — but the end result for patients can feel the same.

Why Rexulti is harder to find than many other medications

Rexulti scores a 62 out of 100 on Medfinder's findability scale — meaning it's generally available at major pharmacies but can be hard to locate at smaller or independent locations. Several factors drive this:

• Brand-name only, high cost. At roughly $1,500 per month, pharmacies don't stockpile Rexulti speculatively. They order it per patient, creating gaps when wholesale supply is disrupted.
• No generic competition. Although the FDA approved a generic from Alembic Pharmaceuticals in early 2025, patent protections held by Otsuka and Lundbeck are expected to block market entry until as late as 2032–2033. With one manufacturer and one brand, there's no backup supply chain.
• Multiple strengths, uneven stocking. Rexulti comes in six strengths (0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg). Pharmacies may carry the most popular strengths but not others, making titration doses particularly hard to find.
• Insurance barriers. Many plans require prior authorization or step therapy before covering Rexulti, which can create delays that patients experience as the prescription being unavailable.

What's the status of generic brexpiprazole in 2026?

The FDA approved a generic version of brexpiprazole from Alembic Pharmaceuticals in January 2025. However, FDA approval does not mean the generic can be sold. Rexulti is protected by multiple patents and regulatory exclusivities, with key formulation patents potentially blocking generic market entry until 2032 or later.

When generic brexpiprazole does eventually reach the market, competition is expected to drive the price down by 80% or more, dramatically improving both affordability and pharmacy availability. But patients should not expect this in 2026.

What about the 2026 Medicare Part D changes?

The Medicare Part D out-of-pocket cap of $2,100 per year took effect in 2026. This is significant for Medicare patients taking Rexulti, as it limits total annual out-of-pocket drug costs. However, it doesn't solve the availability problem at the pharmacy counter — it only addresses what patients pay once they find their medication.

Medicare patients who previously couldn't afford Rexulti due to high early-phase costs may find it more accessible financially in 2026, which could actually increase demand and temporarily tighten supply at certain locations.

What patients should do right now

If you're struggling to fill Rexulti in 2026, don't just wait. Use Medfinder to search real-time pharmacy inventory near you. Read our complete guide on how to find Rexulti in stock for step-by-step strategies, and contact Otsuka Patient Support at 1-833-468-7852 for additional help.

If you've been experiencing ongoing delays, consider switching to a mail-order pharmacy that specializes in specialty medications — they often have more reliable supply. And if insurance is the barrier, ask your prescriber's office to assist with prior authorization paperwork.